TISSUE-TYPE PLASMINOGEN-ACTIVATOR, TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND THEIR COMPLEX IN PLASMA WITH DISSEMINATED INTRAVASCULAR COAGULATION

被引:17
|
作者
FUKAO, H
UESHIMA, S
OKADA, K
YAMAMOTO, K
MATSUO, T
MATSUO, O
机构
[1] KINKI UNIV,SCH MED,DEPT PHYSIOL,OSAKA 589,JAPAN
[2] DEPT INTERNAL MED,SUMOTO 656,JAPAN
关键词
TISSUE-TYPE PLASMINOGEN ACTIVATOR; TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR; T-PA/PAI-1; COMPLEX; ENDOTHELIAL CELLS; DISSEMINATED INTRAVASCULAR COAGULATION;
D O I
10.1016/0049-3848(92)90127-V
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The levels of tissue-type plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and t-PA/PAI-1 complex antigens were analyzed in the plasma of disseminated intravascular coagulation (DIC) patients and healthy controls. Other fibrinolytic parameters such as the levels of plasminogen, alpha2-antiplasmin (alpha2-AP), plasmin/alpha2-AP (PAP), and D-dimer were also estimated to clarify the fibrinolytic states in these plasmas. The antigens of t-PA, PAI-1, and t-PA/PAI-1 complex were found to increase from 8.5 +/- 4.3, 54.4 +/- 21.2, and 8.6 +/- 3.5 ng/ml in normal plasma to 36.4 +/- 25.1, 106.8 +/- 54.7, and 46.6 +/- 34.5 ng/ml in DIC plasma, respectively. The molar ratio of total t-PA to total PAI-1 was 1 : 6 and 1 : 3 in normal plasma and DIC plasma, respectively, indicating an enhanced fibrinolytic state in the DIC plasma. The DIC plasma revealed a significant consumption of plasminogen (62.1 +/- 27.8%), and alpha2-AP (63.7 +/- 25.3%) and an increase in PAP (2.6 +/- 2.7 mug/ml) and D-dimer (3.9 +/- 10.7 mug/ml). These results suggest that the production and secretion of t-PA and PAI-1 from endothelial cells were enhanced in DIC, resulting in an increased t-PA/PAI-1 complex with dominant fibrinolytic activity.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [11] TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR AND TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) LYMPHOCYTES
    ANKRI, A
    MENTZ, F
    CHEVRET, S
    COUTY, MC
    BINET, JL
    BLOOD, 1994, 84 (10) : A459 - A459
  • [12] TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN NORMAL AND ENDOTOXIN-TREATED RAT AORTA
    QUAX, PHA
    PADRO, T
    EMEIS, JJ
    VANDENHOOGEN, RM
    VERHEIJEN, JH
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 834 - 834
  • [13] THE ROLE OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN THE CLEARANCE OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY RAT HEPATOMA-CELLS
    CAMANI, C
    BACHMANN, F
    KRUITHOF, EKO
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1994, 269 (08) : 5770 - 5775
  • [14] KINETICS OF INHIBITION OF TISSUE-TYPE AND UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 AND TYPE-2
    THORSEN, S
    PHILIPS, M
    SELMER, J
    LECANDER, I
    ASTEDT, B
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1988, 175 (01): : 33 - 39
  • [15] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    MCDONALD, C
    SHUMAN, M
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1985, 366 (09): : 823 - 824
  • [16] TISSUE-TYPE PLASMINOGEN-ACTIVATOR ANTIGEN AND PLASMINOGEN-ACTIVATOR INHIBITOR IN DIABETES-MELLITUS
    AUWERX, J
    BOUILLON, R
    COLLEN, D
    GEBOERS, J
    ARTERIOSCLEROSIS, 1988, 8 (01): : 68 - 72
  • [17] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    TURAZZA, FM
    POGNA, M
    MEDICINA-RIVISTA DELLA ENCICLOPEDIA MEDICA ITALIANA, 1990, 10 (01): : 75 - 78
  • [18] TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    LIJNEN, HR
    COLLEN, D
    ANNALES DE BIOLOGIE CLINIQUE, 1987, 45 (02) : 198 - 201
  • [19] TISSUE-TYPE PLASMINOGEN-ACTIVATOR, PLASMINOGEN-ACTIVATOR INHIBITOR AND D-DIMER IN MALIGNANCY
    FERNANDEZ, J
    PARAMO, JA
    CUESTA, B
    HERNANDEZ, M
    PALOMA, MJ
    RIFON, J
    ROCHA, E
    BIOCHEMISTRY, BIOLOGICAL FUNCTIONS, GENE REGULATION AND EXPRESSION, 1988, 801 : 329 - 332
  • [20] PLASMA CHANGES OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 DURING CORONARY THROMBOLYSIS WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR
    OTTANI, F
    GALVANI, M
    NICOLINI, FA
    RONCHI, A
    FERRINI, D
    RUSTICALI, F
    CIRCULATION, 1993, 88 (04) : 320 - 320